This clinical trial is conducted in Europe. The purpose of the trial is to investigate the influence on the pharmacokinetics (the rate at which the trial drug is eliminated from the body) of an oral contraceptive combination drug after multiple administration of semaglutide in female subjects with type 2 diabetes.

An Open-label, One-sequence Cross-over, Single Centre Trial Investigating the Influence of Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug After Multiple Dose Administration of Semaglutide in Subjects With Type 2 Diabetes

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:

Area under the ethinylestradiol concentration-time curve [ Time Frame: in the 24 hour dosing interval ] [ Designated as safety issue: No ]

Area under the levonorgestrel concentration-time curve [ Time Frame: in the 24 hour dosing interval ] [ Designated as safety issue: No ]

Family or personal history of multiple endocrine neoplasia type 2 (MEN2), or family history of medullary thyroid cancer (FMTC)

Personal history of non-familial medullary thyroid carcinoma

Subjects who are considered at increased risk of thrombosis formation, such as deep vein thrombosis, pulmonary embolism, infarction or apoplexy (as judged by the trial physician) and subjects who are smokers

Blood or plasma donation within the last 3 months prior to first dosing

Participation in any other trial investigating other products or involving blood sampling within the last 3 months prior to first dosing

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01324505